Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity.

BACKGROUND: The endocannabinoid system is active in nervous and immune cells and involves the expression of two cannabinoid receptor genes (CB1 and CB2), along with endogenous endocannabinoid ligands, 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide), and their synthetic enzymes. Cannabidiol (CBD) is a non-intoxicating exogenous cannabinoid agonist derived from plants that, at high doses, has received FDA approval as an anticonvulsant for epileptic seizures, and at low doses is marketed as a food-grade supplement for improved mental health, sleep quality, and immunological function. At present, the predominance of published CBD clinical research has focused on ameliorative or disease-specific intervention, with few trials investigating CBD effects in healthy populations. METHODS: This clinical study aimed to investigate the effects of 8 weeks of 50 mg oral CBD on mental health, sleep quantity and quality, and immune cell function in healthy, college-aged individuals. Twenty-eight participants (average age 25.9 ± 6.1 y) were randomized to receive either daily oral capsules of 50 mg of CBD (CB, n = 14) or a calorie-matched placebo (CN, n = 14). Participants completed pre- and post-intervention assessments, including anthropometric measurements, mental health surveys, sleep analysis, and immunological function assessments. RESULTS: After completing the 8-week intervention, there were no significant changes in body weight and BMI (CN: 1.09 ± 0.89%: CB: 1.41 ± 1.07%), or body fat percentage (CN: 9.01 ± 7.51%: CB: 8.57 ± 7.81%), respectively (values are % change pre to post, p > 0.05). There were also no significant differences between CB and CN groups with respect to mental health measures, sleep quantity, or circulating immunophenotype as a result of the intervention. However, the CB group experienced significant improvements in sleep quality measured objectively using a sleep questionnaire (p = 0.0023) and enhanced Natural Killer (NK) immune cell function assessed in situ (p = 0.0125). CONCLUSIONS: Eight weeks of daily 50 mg CBD may improve sleep quality, and NK immunosurveillance in healthy, younger adults.

Effects of Oral Cannabidiol on Health and Fitness in Healthy Adults: An 8-Week Randomized Trial.

BACKGROUND: There is a lack of research on the effects of cannabidiol (CBD) on health-related fitness, physical activity, cognitive health, psychological wellbeing, and concentrations of C-reactive protein (CRP) in healthy individuals. CBD has potential anti-inflammatory and neuroprotective effects. METHODS: This study aimed to investigate the effects of 8 weeks of CBD on the above-mentioned measures in healthy individuals. Forty-eight participants were randomized into two groups receiving either oral capsules of 50 mg of CBD or a calorie-matched placebo daily. Participants completed pre- and post-intervention assessments, including blood draws, body composition, fitness, physical activity, and self-reported surveys. RESULTS: There were no significant differences between groups regarding body composition, aerobic fitness, muscular strength, physical activity, cognitive health, psychological wellbeing, and resting CRP concentrations. However, the placebo group experienced a decline in mean peak power and relative peak power compared to the CBD group. CONCLUSIONS: The results suggest that 8 weeks of CBD supplementation may prevent declines in anaerobic fitness over time. However, long-term CBD supplementation may not be beneficial for altering measures of health-related fitness, mental health, and inflammation in healthy individuals.

Regular Use of Cannabis in Female Athletes Is Associated With a Reduction in Early Anaerobic Power Production.

ABSTRACT: Lisano, JK, Flores, VA, Kisiolek, JN, and Stewart, LK. Regular use of cannabis in female athletes is associated with a reduction in early anaerobic power production. J Strength Cond Res 37(3): 616-622, 2023-Despite a growing number of claims related to the ability of cannabis use to affect health and performance, there is limited research available, especially in female athletes. This cross-sectional study aimed to determine whether chronic cannabis use in physically active female athletes is related to altered health and performance. Healthy, physically active, female cannabis users (CU: n = 12) and noncannabis users (NU: n = 12) with an average age of 23.8 ± 3.7 years and 19.3 ± 4.2% body fat completed athletic performance and health assessments. Significance was set at alpha = 0.05. The age of onset of regular cannabis use was 20.1 ± 2.8 years in CU with an average duration of cannabis use of 5.8 ± 3.1 years. There were no differences between groups with respect to body size, body composition, pulmonary function, cardiorespiratory function, or muscular strength. Cannabis users produced significantly less power in the first 2 stages of the Wingate assessment, but CU experienced significantly less anaerobic fatigue. Although body composition and cardiovascular fitness were comparable, average C-reactive protein concentration classified CU with higher risk for cardiovascular disease (CVD). Athletes and coaches who rely heavily on anaerobic performance should consider these findings because they indicate that regular cannabis use may affect early power production and CVD risk.

Short Term, Oral Supplementation with Optimized Curcumin Does Not Impair Performance Improvements Associated with High Intensity Interval Training.

Curcumin may improve athletic performance through a reduction in inflammation following exercise and improve mental states of well-being. The purpose of this investigation was to explore the effects of a 14 day HIIT intervention and oral supplementation with Longvida® optimized curcumin on athletic performance, lactate response, and well-being. Sixteen males and twenty females participated in a double-blinded, randomized, placebo-controlled trial to explore the effects of Longvida(R) optimized curcumin (1.0 g/day) and or a placebo (PLA) taken daily during a 14 day HIIT protocol. Participants were randomized into two groups, then evaluated in three groups, curcumin-fast (CURF), curcumin-slow (CURS) and placebo. Curcumin-fast and curcumin-slow were separated by their 16.1 km cycling time trial performance (TT) with CURF and CURS determined by a TT <30 min and >30 min at the pre intervention time point, respectively. Cycling time-trial performance, blood lactate response, and well-being assessments were determined at pre and post 14 day HIIT intervention time points. Blood lactate was recorded at baseline, 8.01 km, 15.1 km, and 1 min post, and 4 min post of the pre and post intervention TT. Following the internvetion, CONP and CURS experienced with 8.15% and 5.04% improvements in TT performance times, while CURF experienced a 0.57% improvement in TT performance time. No changes were observed with respect to other measures. When curcumin is taken daily in conjunction with 14 days of HIIT on a cycle ergometer, cycling performance in either well trained or more recreationally trained athletes is not impaired. Although the improvements in TT performance were not stasticially significant, they are noteworthy.

Sleep Duration Correlates With Performance in Ultra-Endurance Triathlon.

The relationship between sleep duration, sleep quality, and race completion time during each stage of a 3-day ultra-endurance triathlon (stage 1: 10-km swim, 146-km cycle; stage 2: 276-km cycle; and stage 3: 84.4-km run) was investigated. Seventeen triathletes partook in sleep analysis throughout the ultra-endurance multiday triathlon using an actigraphy wristband. The participants wore the band to record objective sleep outcomes for approximately 4 days (1-2 d prerace, 3 race days, and 1 d postrace), except while racing. The total sleep time (TST; prerace: 414.1 [95.3] min, prestage 1: 392.2 [138.3] min, prestage 2: 355.6 [62.5] min, and prestage 3: 299.7 [107.0] min) significantly decreased over time (P < .05). Significant Pearson moment-product correlations were found between TST and subsequent race-day performance for race stage 1 (r = -.577; P = .019) and stage 3 (r = -.546; P = .035), with further analysis revealing that TST explained 33% and 30% of the variation in performance for stages 1 and 3, respectively. During a 3-day ultra-endurance triathlon, the TST was reduced and had a significant negative correlation to exercise performance, indicating that sleep loss was associated with slower performances. Sleep onset latency, wake episodes, and sleep efficiency did not significantly change over the course of this investigation, which may stem from the close proximity of exercise to sleep.

Relationship between training load and recovery in collegiate American football players during pre-season training.

Background: The purpose of this study was to examine the relationship between training load and next-day recovery in collegiate American football (AF) players during pre-season.Methods: Seventeen athletes (Linemen, n = 6; Non-linemen, n = 11) participated in the 14-day study wearing monitoring (accelerometer + heart rate) sensors during on-field practice sessions throughout pre-season to assess the physiological (PL), mechanical load (ML) and recording of session RPE (sRPE load) immediately post-practice. Prior to practice, participants completed a drop-jump reactive strength index (RSI) test and reported perceived recovery status (PRS). Loaded counter movement vertical jump was assessed before and after pre-season.Results: For every one unit increase in sRPE load, RSI declined by 0.03. Non-linemen had a lower RSI value of 73.1 units compared to linemen. For every one unit increase in ML, the PRS decreased by 0.01. Non-linemen recorded higher average ML during week 2 (ES = 1.17) compared to linemen. Non-linemen recorded higher RSI values in weeks 1 (ES = -1.41) and 2 (ES = -1.72) compared to linemen. All training load and recovery parameters were lower week 2 compared to week 1 (p < 0.05) for all players.Conclusions: Next-day RSI values were influenced by sRPE load while next-day PRS appears to be more influenced by ML. No difference in PL or sRPE load was observed been groups despite non-linemen completing a higher ML throughout the preseason. A combination of training load and recovery metrics may be needed to monitor the fatigue and state of readiness of each player.

Chronic cannabis use and circulating biomarkers of neural health, stress, and inflammation in physically active individuals.

Previous research has associated cannabis use with altered circulating neurotrophins and biomarkers of immune health, but these relationships have yet to be fully explored in physically active individuals. The specific aim of this study was to explore the relationships between biomarkers of neural health: nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), immune health: interleukin 6 (IL-6), C-reactive protein (CRP), and cortisol, as well as the presence of depression, in physically active cannabis users (CU) and nonusers (NU). Male and female participants (N = 30; CU, n = 15, NU, n = 15) provided intravenous blood samples and underwent assessment of body composition, maximal oxygen consumption, and depression (Beck Depression Inventory-II (BDI-II)). Samples were analyzed for concentrations of NGF, BDNF, IL-6, CRP, and cortisol using ELISAs. CU and NU were compared using an unpaired t test. Pearson's correlation and multiple linear regression were used to evaluate relationships among variables. There were no significant differences in body size or composition, maximal oxygen consumption, total BDI-II Score, concentrations of NGF, IL-6, CRP, or cortisol between groups. BDNF was significantly lower in CU compared with NU (p = 0.02), with a significant negative relationship between BDNF and CRP (p = 0.02). Mean concentrations of CRP placed CU at higher risk for cardiovascular disease compared with NU. Total BDI-II score negatively correlated with BDNF (p = 0.02) and positively correlated with CRP (p = 0.02). Novelty Plasma BDNF was significantly lower in physically active cannabis users compared with NU. CU were classified at moderate risk for cardiovascular disease based on average circulating CRP compared with low risk for NU.

Ultra-endurance triathlon performance and markers of whole-body and gut-specific inflammation.

PURPOSE: To examine the influence of the Ultraman Florida triathlon (3 days of non-continuous racing; stage 1: 10 km swim and 144.8 km cycle; stage 2: 275.4 km cycle; stage 3: 84.4 km run) on circulating plasma concentrations of whole-body (C-reactive protein (CRP), interleukin (IL)-6 (IL-6), and IL-10 and surrogate gut-specific inflammatory markers (IL-17 and IL-23), and determine whether these variables are associated with performance. METHODS: Eighteen triathletes (N = 18; 15 men, 3 women; age: 37 ± 8 yrs) were evaluated at baseline and post-race for circulating concentrations of CRP, IL-6, IL-10, IL-17, and IL-23. Blood samples were drawn two days prior to stage 1 (1600 h) and one day after stage 3 (1200 h). RESULTS: Plasma CRP significantly increased from baseline (1985.8 ± 5962.3 ng/mL) to post-race (27,013.9 ± 12,888.8 ng/mL, p < 0.001, 13-fold increase). Both plasma IL-6 and IL-10 did not significantly change from baseline to post-race. Baseline and post-race concentrations of IL-17 and IL-23 were below detectable limits. Pearson's correlation between mean finish time and post-race IL-10 revealed a significant positive correlation (r = 0.54, p < 0.05). CONCLUSIONS: Our results suggest that cytokines such as IL-6 and IL-10 involved in the inflammatory response return to near-baseline concentrations rapidly even after ultra-endurance events of extreme duration. The absence of IL-17 and IL-23 may suggest positive gut adaptations from ultra-endurance training. A significant positive correlation between post-race IL-10 concentrations and mean finish time may indicate that a relationship between anti-inflammatory responses and performance exists.

The effect of cold ambient temperature and preceding active warm-up on lactate kinetics in female cyclists and triathletes.

The aim of this study was to evaluate the effect of cold ambient temperature on lactate kinetics with and without a preceding warm-up in female cyclists/triathletes. Seven female cyclists/triathletes participated in this study. The randomized, crossover study included 3 experimental visits that comprised the following conditions: (i) thermoneutral temperature (20 °C; NEU); (ii) cold temperature (0 °C) with no active warm-up (CNWU); and (iii) cold temperature (0 °C) with 25-min active warm-up (CWU). During each condition, participants performed a lactate threshold (LT) test followed by a time to exhaustion trial at 120% of the participant's peak power output (PPO) as determined during prior peak oxygen consumption testing. Power output at LT with CNWU was 10.2% ± 2.6% greater than with NEU, and the effect was considered very likely small (effect size (ES) = 0.59, 95%-99% likelihood). Power output at LT with CNWU was 4.2% ± 5.4% greater than with CWU; however, the effect was likely trivial (ES = 0.25, 75%-95% likelihood). At LT, there were no significant differences between interventions groups in oxygen consumption, blood lactate concentration, heart rate, or rating of perceived exertion. Time to exhaustion at 120% at PPO was 11% longer with CNWU than with CWU (ES = 0.62, respectively), and this effect was likely small. These findings suggest that power output at LT was higher in CNWU compared with NEU. Additionally, time to exhaustion at 120% of PPO was higher in CNWU compared with CWU and no different than NEU; these differences likely result in a small improvement in performance with CNWU versus CWU and NEU.

Adipose Lipolysis Unchanged by Preexercise Carbohydrate Regardless of Glycemic Index.

PURPOSE: This study aimed to determine the effect of preexercise carbohydrate of different glycemic indices on subcutaneous abdominal adipose tissue (SCAAT) metabolism and running performance. METHODS: Ten trained male runners completed three experimental trials consisting of 30 min at 60% maximal oxygen consumption, 30 min at 75% maximal oxygen consumption, and a 5-km time trial. Thirty minutes before exercise, participants consumed one of three beverages: 1) 75 g low glycemic index modified starch supplement (UCAN), 2) 75 g high glycemic index glucose-based supplement (G), or 3) a flavor-matched noncaloric placebo (PL). SCAAT lipolysis was assessed via microdialysis. RESULTS: Before exercise, blood glucose and insulin were elevated with G versus PL (+53.0 ± 21.3 mg·dL (mean ± SD), P < 0.0001; +33.9 ± 11.0 µU·mL, P < 0.0001) and G versus UCAN (+36.6 ± 24.9 mg·dL, P < 0.0001; +25.2 ± 11.0 µU·mL, P < 0.0001), respectively. Fat oxidation was attenuated, and carbohydrate oxidation increased before exercise with G versus PL (-0.06 ± 0.06 g·min, P = 0.005; +0.18 ± 0.07 g·min, P < 0.0001) and G versus UCAN (-0.06 ± 0.05 g·min, P = 0.004; +0.18 ± 0.14 g·min, P < 0.0001). However, there were no differences in SCAAT lipolysis at rest or during running at either exercise intensity. Also, there was no effect of treatment on running performance. CONCLUSIONS: Preexercise carbohydrate lowers fat oxidation and increases carbohydrate oxidation, and these effects are attenuated with low glycemic index carbohydrate. However, these changes are not the result of alterations in SCAAT lipolysis, nor do they affect running performance.